Want to see HK:2160 full AI Analyst Report?
MicroPort CardioFlow Medtech Corp. (2160) AI Stock Analysis
MicroPort CardioFlow Medtech Corp.
(HKEX:2160)
The score is held down primarily by weak financial quality—widening losses, negative free cash flow, and a sharp step-up in leverage that increases balance-sheet risk. Technicals are comparatively better, showing improving near-term momentum, but valuation remains constrained by loss-making results and no dividend support.
MicroPort CardioFlow Medtech Corp. (2160) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 634.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.02M
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- 1.73
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 1,415
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model
Company Description
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily wi...
How the Company Makes Money
The company primarily makes money by selling medical devices and procedure-related consumables used in cardiovascular interventions to healthcare providers (such as hospitals and distributors). Revenue is generally generated per unit sold (or per pro...
MicroPort CardioFlow Medtech Corp. Financial Statement Overview
Summary
Revenue is growing (+8.7% YoY in 2025) with solid gross margin (~55%), but losses widened (net margin about -33%), operating cash flow is slightly negative, and free cash flow remains meaningfully negative. The largest constraint is the sharp increase in leverage (debt ~1.62B; ~6.3x debt-to-equity), which materially raises financial risk while the company is still loss-making.
Income Statement
34NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 440.17M | 443.79M | 49.52M | 47.47M | 36.66M | 31.53M |
| Gross Profit | 240.57M | 288.34M | 34.41M | 32.46M | 23.68M | 18.64M |
| EBITDA | -9.89M | -41.02M | -6.61M | -54.51M | -42.10M | ― |
| Net Income | -144.20M | -146.41M | -6.77M | -66.58M | -66.37M | -28.78M |
Balance Sheet | ||||||
| Total Assets | 745.01M | 5.21B | 366.47M | 363.87M | 438.35M | 527.92M |
| Cash, Cash Equivalents and Short-Term Investments | 1.38B | 1.39B | 186.10M | 150.38M | 303.11M | 379.68M |
| Total Debt | 258.36M | 1.81B | 10.53M | 9.95M | 13.94M | 19.73M |
| Total Liabilities | 459.95M | 3.22B | 62.19M | 34.20M | 36.16M | 41.69M |
| Stockholders Equity | 1.99B | 1.99B | 299.56M | 329.67M | 402.20M | 486.23M |
Cash Flow | ||||||
| Free Cash Flow | -567.65M | -297.74M | -36.99M | -33.53M | -33.83M | -42.39M |
| Operating Cash Flow | -25.49M | -25.82M | -15.29M | -29.22M | -26.66M | -25.36M |
| Investing Cash Flow | 434.43M | 404.12M | -109.36M | -84.16M | -26.26M | -68.69M |
| Financing Cash Flow | 275.10M | 44.33M | -7.71M | -3.62M | -19.93M | 349.61M |
MicroPort CardioFlow Medtech Corp. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2160, the sentiment is Negative. The current price of 1.28 is below the 20-day moving average (MA) of 1.28, below the 50-day MA of 1.29, and below the 200-day MA of 2.29, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 49.97 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2160.
MicroPort CardioFlow Medtech Corp. Peers Comparison
Overall Rating
HK:660985Outperform
HK:178972Outperform
HK:130256Neutral- HK:216048Neutral
HK:250044Neutral
HK:085341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6609 | 85Outperform | HKD 2.18B | 18.16 | 7.90% | ― | 59.30% | 131.03% |
| HK:1789 | 72Outperform | HKD 5.05B | 11.36 | 13.24% | 2.59% | 16.15% | 31.89% |
| HK:1302 | 56Neutral | HKD 6.35B | 98.02 | 1.71% | ― | 0.75% | -20.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2160 | 48Neutral | HKD 1.63B | -0.86 | -6.69% | ― | ― | ― |
| HK:2500 | 44Neutral | HKD 432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% |
| HK:0853 | 41Neutral | HKD 11.65B | 31.23 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2160 | MicroPort CardioFlow Medtech Corp. | 1.28 | -4.67 | -78.49% | |
| HK:0853 | MicroPort Scientific Corp | 6.08 | -5.92 | -49.33% | |
| HK:1302 | LifeTech Scientific Corporation | 1.47 | -0.58 | -28.29% | |
| HK:1789 | AK Medical Holdings Ltd. | 4.56 | -1.34 | -22.75% | |
| HK:2500 | Venus Medtech (Hangzhou), Inc. Class H | 0.98 | -1.77 | -64.36% | |
| HK:6609 | Shanghai Heartcare Medical Technology Corp. Ltd. Class H | 53.20 | -0.30 | -0.56% |
MicroPort CardioFlow Medtech Corp. Corporate Events
MicroPort CardioFlow Restructures Leadership and Board to Strengthen Governance
MicroPort CardioFlow Medtech Corp. has reshuffled its senior leadership and board roles, reassigning key executives while maintaining continuity in strategic oversight. The changes are effective August 26, 2026 and involve updates to the composition...
MicroPort CardioFlow Sets Out Board Composition and Committee Roles
MicroPort CardioFlow Medtech Corp. has detailed the composition of its board of directors and clarified the roles held by each member, underscoring a governance framework that mixes executive, non-executive, and independent oversight. The board is le...
MicroPort CardioFlow Delays Board Meeting to Complete Lease Evaluation for Interim Results
MicroPort CardioFlow Medtech Corporation has postponed its previously scheduled board meeting from August 26 to August 31, 2026, delaying consideration and approval of the group’s interim results for the six months ended June 30, 2026. The meet...
MicroPort CardioFlow Medtech Sets Board Meeting to Approve Interim Results and Consider Dividend
MicroPort CardioFlow Medtech Corporation, a Cayman Islands-incorporated cardiovascular medical technology company listed in Hong Kong and operating from Shanghai, develops interventional devices and solutions targeting heart disease treatment in Chin...
MicroPort CardioFlow Signals Revenue Surge as CRM Acquisition Fuels Global Growth
MicroPort CardioFlow Medtech expects to report at least US$153 million in revenue and a net loss capped at US$25 million for the first half of 2026, reflecting the first full consolidation of its newly acquired cardiac rhythm management business. The...
MicroPort CardioFlow signs two major Shanghai production leases
MicroPort CardioFlow Medtech has entered into two five-year lease agreements in Shanghai through its subsidiaries MP CardioFlow and MicroPort CRM Shanghai, effective from August 1, 2026 to July 31, 2031. The first lease covers a 9,042.09 sq.m propert...
MicroPort CardioFlow Grants 440,000 Share Options Under 2023 Incentive Scheme
MicroPort CardioFlow Medtech Corp. has granted 440,000 share options to three group employees under its share scheme adopted in 2023, allowing each option holder to subscribe for one ordinary share at an exercise price of HK$1.678. The options, which...
MicroPort CardioFlow Wins Shareholder Backing for AGM Resolutions and Capital Mandates
MicroPort CardioFlow Medtech Corp. reported that all resolutions at its annual general meeting on June 4, 2026, were duly approved by shareholders via poll, including the receipt of 2025 audited financial statements. Shareholders also renewed mandate...
MicroPort CardioFlow Sets Board Lineup and Committee Structure
MicroPort CardioFlow Medtech Corp. has announced the composition of its board of directors, led by non-executive chairman Chen Guoming and co-chairman Brian Chang, alongside executive directors Zhang Ruinian, the chief executive officer, and presiden...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026